Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CAPITROL vs ACETAMINOPHEN AND IBUPROFEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ciclopirox is a hydroxypyridine antifungal agent that inhibits the uptake of essential elements and amino acids, disrupts fungal cell membrane integrity, and chelates polyvalent cations (e.g., Fe3+, Al3+), inhibiting metal-dependent enzymes such as cytochromes and catalase.
Acetaminophen is a centrally acting analgesic and antipyretic whose exact mechanism is not fully understood, but is thought to involve inhibition of cyclooxygenase (COX) in the brain and modulation of cannabinoid receptors. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that non-selectively inhibits COX-1 and COX-2, reducing prostaglandin synthesis.
Topical treatment of seborrheic dermatitis of the scalp in adults
Temporary relief of minor aches and pains,Reduction of fever,Off-label: Management of osteoarthritis pain, headache, dysmenorrhea
Apply 1 m L of 1% shampoo twice weekly for 4 weeks, then weekly for maintenance. Use on wet hair, lather for 2-3 minutes, rinse thoroughly.
Oral: Acetaminophen 325 mg and ibuprofen 200 mg, 1-2 tablets every 6 hours as needed, not exceeding 6 tablets/24 hours.
Terminal elimination half-life is 20-40 hours; clinically, steady-state is achieved within 5-7 days.
Acetaminophen: 2-3 hours (normal hepatic function). Ibuprofen: 2-4 hours (immediate-release); prolonged in overdose or hepatic impairment.
Ciclopirox is primarily metabolized via glucuronidation, with less than 2% excreted unchanged in urine. The major metabolite is ciclopirox glucuronide.
Acetaminophen is primarily metabolized via glucuronidation and sulfation; a minor pathway via CYP2E1 produces a toxic metabolite, NAPQI. Ibuprofen is metabolized primarily by CYP2C9 and to a lesser extent by CYP2C8.
Primarily renal (approximately 60-70% as unchanged drug); biliary/fecal elimination accounts for about 20-30%.
Acetaminophen: renal excretion of metabolites (glucuronide 55%, sulfate 30%, cysteine/mercapturate <10%); <5% unchanged. Ibuprofen: renal excretion of metabolites (conjugates) 90%; <10% unchanged; minor biliary/fecal.
>99% bound to albumin and alpha-1-acid glycoprotein.
Acetaminophen: 10-25% (albumin). Ibuprofen: >99% (albumin).
0.3 L/kg; indicates distribution primarily into extracellular fluid.
Acetaminophen: 0.9 L/kg; Ibuprofen: 0.15 L/kg (highly protein-bound, low Vd).
Oral: 70-80%; Topical: approximately 5-10%.
Acetaminophen: 75-85% oral. Ibuprofen: 80-100% oral.
No adjustment required as systemic absorption is negligible.
GFR 30-59: Caution, use lowest effective dose; GFR <30: Contraindicated due to ibuprofen component.
No adjustment required as systemic absorption is negligible.
Child-Pugh A: No adjustment; Child-Pugh B: Caution, reduce acetaminophen dose; Child-Pugh C: Contraindicated.
Safety and efficacy not established in children under 12 years; use same as adult for ages 12 and above.
Weight-based: 10-15 mg/kg acetaminophen + 5-10 mg/kg ibuprofen per dose, every 6-8 hours, max 4 doses/day.
No specific dose adjustment; caution with dry or aged skin due to potential irritation.
Use lowest effective dose; monitor renal function due to ibuprofen; avoid durations >10 days.
None.
Acetaminophen may cause severe liver injury, including acute liver failure, at doses exceeding 4,000 mg/day. Ibuprofen: NSAIDs increase risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. Risk increases with duration of use and in patients with cardiovascular risk factors. NSAIDs also increase risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of stomach or intestines.
Avoid contact with eyes,If irritation or sensitization occurs, discontinue use,Not for oral, ophthalmic, or intravaginal use
Acetaminophen: Hepatotoxicity risk with excessive doses, use with caution in hepatic impairment, avoid with alcohol use >3 drinks/day. Ibuprofen: Cardiovascular risk, gastrointestinal bleeding, renal toxicity, hypertension, fluid retention, avoid late pregnancy.
Hypersensitivity to ciclopirox or any component of the formulation
Acetaminophen: Severe hepatic impairment, allergy to acetaminophen. Ibuprofen: Hypersensitivity to ibuprofen or other NSAIDs, history of asthma/urticaria after NSAIDs, perioperative pain in CABG surgery, severe heart failure, active GI bleeding, late pregnancy.
No known food interactions when applied topically. However, avoid applying immediately before consuming food to minimize accidental ingestion.
Avoid alcohol; take with food or milk to minimize GI irritation. No specific food restrictions.
No adequate human studies; animal studies not available. Only minimal systemic absorption occurs with topical scalp application; theoretical risk low. First trimester: unlikely to cause harm due to negligible absorption; however, avoid elective use. Second and third trimesters: no known risks.
First trimester: Acetaminophen is considered low risk; ibuprofen is associated with increased risk of miscarriage and cardiac defects. Second trimester: Acetaminophen is safe; ibuprofen is relatively safe but may cause oligohydramnios. Third trimester: Acetaminophen is safe; ibuprofen is contraindicated due to risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment.
Minimal systemic absorption; expected to be safe during breastfeeding. M/P ratio not determined. Avoid application to breast area.
Acetaminophen: low levels in breast milk, M/P ratio ~0.9; considered compatible with breastfeeding. Ibuprofen: minimal excretion, M/P ratio ~0.01; considered compatible. Combination: low risk with recommended doses.
No dose adjustment required; topical use only.
No standard adjustment for acetaminophen; ibuprofen dosing unchanged in pregnancy but avoid in third trimester; consider increased clearance of acetaminophen in pregnancy but no dose adjustment recommended.
Capitrol (chloroxine) is a topical antibacterial shampoo indicated for dandruff and seborrheic dermatitis. It is generally used twice weekly for 2 weeks, then as needed. Avoid contact with eyes and mucous membranes. Discontinue if local irritation or allergic reaction occurs.
Combination product for acute pain; fixed-dose may exceed recommended daily acetaminophen limit if other acetaminophen-containing products are used. Onset of ibuprofen is 30-60 min, acetaminophen 15-30 min; duration 4-6 hours. Caution in renal impairment (ibuprofen) and hepatic impairment (acetaminophen). Avoid in third trimester of pregnancy.
Use exactly as directed; do not use more often than prescribed.,Wet hair and scalp thoroughly before applying shampoo.,Massage into scalp and leave on for 2-3 minutes before rinsing.,Avoid contact with eyes; if occurs, rinse thoroughly with water.,Use caution to avoid staining of clothing or jewelry; rinse shampoo off completely.,Consult healthcare provider if condition persists or worsens after 2 weeks.,Inform doctor if you are pregnant, planning to become pregnant, or breastfeeding.
Do not exceed 10 tablets (500 mg acetaminophen/200 mg ibuprofen) per day.,Do not take with other products containing acetaminophen or NSAIDs.,Take with food or milk to reduce stomach upset.,Avoid alcohol while taking this medication.,Seek medical help if pain persists >10 days or fever >3 days.,Store at room temperature, away from moisture.
No interactions on record
"Concomitant use of Ibuprofen (a nonsteroidal anti-inflammatory drug, NSAID) and Methylprednisolone (a systemic corticosteroid) synergistically increases the risk of gastrointestinal (GI) ulceration, bleeding, and perforation due to additive inhibition of prostaglandin synthesis and mucosal protection. Additionally, Ibuprofen may potentiate the immunosuppressive effects of Methylprednisolone, elevating infection risk. This interaction can lead to serious clinical outcomes, including acute GI hemorrhage, perforation, and impaired wound healing."
"The combination of olopatadine, an antihistamine with sedative properties, and ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), may result in additive central nervous system (CNS) depression, leading to increased sedation, dizziness, and impaired psychomotor function. Ibuprofen can inhibit the metabolism of olopatadine via competition for hepatic CYP450 enzymes, potentially elevating olopatadine plasma concentrations and prolonging its systemic effects. Clinically, patients may experience exacerbated drowsiness, reduced alertness, and increased risk of falls or accidents, especially in the elderly or those with compromised hepatic function."
"Ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), can decrease the metabolism of pioglitazone, a thiazolidinedione antidiabetic agent, by inhibiting cytochrome P450 2C8 (CYP2C8) enzyme activity. This inhibition elevates plasma concentrations of pioglitazone, potentially enhancing its hypoglycemic effects and increasing the risk of adverse reactions such as edema, weight gain, and heart failure exacerbation. Clinically, concomitant use may lead to improved glycemic control but also raises concerns for dose-dependent toxicities, necessitating careful monitoring and possible dose adjustment of pioglitazone."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CAPITROL vs ACETAMINOPHEN AND IBUPROFEN, answered by our medical review team.
CAPITROL is a Topical Antimicrobial that works by Ciclopirox is a hydroxypyridine antifungal agent that inhibits the uptake of essential elements and amino acids, disrupts fungal cell membrane integrity, and chelates polyvalent cations (e.g., Fe3+, Al3+), inhibiting metal-dependent enzymes such as cytochromes and catalase.. ACETAMINOPHEN AND IBUPROFEN is a NSAID that works by Acetaminophen is a centrally acting analgesic and antipyretic whose exact mechanism is not fully understood, but is thought to involve inhibition of cyclooxygenase (COX) in the brain and modulation of cannabinoid receptors. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that non-selectively inhibits COX-1 and COX-2, reducing prostaglandin synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CAPITROL and ACETAMINOPHEN AND IBUPROFEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CAPITROL is: Apply 1 m L of 1% shampoo twice weekly for 4 weeks, then weekly for maintenance. Use on wet hair, lather for 2-3 minutes, rinse thoroughly.. The standard adult dose of ACETAMINOPHEN AND IBUPROFEN is: Oral: Acetaminophen 325 mg and ibuprofen 200 mg, 1-2 tablets every 6 hours as needed, not exceeding 6 tablets/24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CAPITROL and ACETAMINOPHEN AND IBUPROFEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CAPITROL is classified as Category C. No adequate human studies; animal studies not available. Only minimal systemic absorption occurs with topical scalp application; theoretical risk low. First trimester: unlikely to . ACETAMINOPHEN AND IBUPROFEN is classified as Category D/X. First trimester: Acetaminophen is considered low risk; ibuprofen is associated with increased risk of miscarriage and cardiac defects. Second trimester: Acetaminophen is safe; ibup. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.